Literature DB >> 1849667

Possibilities of the combined use of non-steroidal anti-inflammatory drugs and sulfhydryl compounds in radioprotection.

A Kozubík1, M Pospísil, J Netíková.   

Abstract

The combined preirradiation administration of indomethacin and cystamine was found to enhance synergistically the recovery of hemopoiesis in sublethally gamma-irradiated mice. This effect can be explained by a common operation of two mechanisms of radioprotection, i.e. of an increased survival of hemopoietic stem cells due to cystamine action and of stimulatory effects of indomethacin on the proliferation of surviving cells, mediated by the inhibition of prostaglandin synthesis. Attempts to prove such enhancement of protective effects on irradiated mice in terms of postirradiation lethality were unsuccessful. The reason seems to be the influence of toxic effects of the indomethacin-cystamine combination on the gastrointestinal tract. When using the less toxic combination, i.e. diclofenac and WR-2721, the additivity of protective effects is manifested even in the survival of lethally irradiated mice. The results suggest that under suitable conditions avoiding the unfavourable toxic effects, non-steroidal anti-inflammatory drugs can be successfully used with the aim to enhance the efficiency of sulfhydryl radioprotectors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849667

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  2 in total

1.  Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells.

Authors:  A Bergamini; M Capozzi; L Ghibelli; L Dini; A Salanitro; G Milanese; T Wagner; S Beninati; C D Pesce; C Amici
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 2.  Brief Story on Prostaglandins, Inhibitors of their Synthesis, Hematopoiesis, and Acute Radiation Syndrome.

Authors:  Michal Hofer; Zuzana Hoferová; Martin Falk
Journal:  Molecules       Date:  2019-11-06       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.